SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
DNDN Analysis & Videos »
DNDN: Bull or Bear?
Access Pharma: A Cancer Biotech Call Option Trade
DNDN
|
|
|
+5.72%
in
44 days
<> The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson (NYSE: JNJ) announcing a $1B cash tender offer for Cougar Biotech (NASDAQ: CGRB) last week and Roche's (VTX: ROG) (OTC: RHHBY) mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon's (NASDAQ: DNDN) Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics (NASDAQ: CTIC) have fueled interest in the small and micro-cap cancer bio-pharma space among investors an...
|
Updated FDA, Clinical Trial Calendars: CTIC, DNDN, MRX, JNJ, MEDX
DNDN
|
|
|
+0.00%
in
1 hour
(closed on 04/14/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/14/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> <>http://biomedreports.c...
|
BioMed Stock Movers: DNDN, EXAS, KG
DNDN
|
|
|
-225.72%
in
6 days
(closed on 04/14/09)
Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation. The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the Company's fate. <> <> <>http://biomedreports.com/article...
|
Bullish on DNDN ...
DNDN
|
|
|
+238.10%
in
95 days
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to improve cancer treatment options for patients. The companyÂ’s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates include Provenge, an active cellular immunotherapy that has completed two phase 3 trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunothe...
|
FDA Calendar Updates: SNTS, CEPH, AZN, DNDN, GILD, NVO
DNDN
|
|
|
-0.73%
in
15 hours
(closed on 04/07/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker...
|
Calendar of 163 FDA Decisions and Clinical Trials
DNDN
|
|
|
+89.63%
in
75 days
(closed on 04/06/09)
The tables at my web link below include an updated calendar of 80 expected FDA new product decisions and 83 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and the below is a summary of new entries and updates on the calendars. <> 1.) Genentech (DNA) expects to report results in mid-April in its Avastin colon cancer adjuvant trial, in addition to pending FDA decisions to expand product labels for Avastin in relaps...
|
UpDown Virtual Investing: Earn Real Money with Zero Risk
DNDN
|
|
|
-3.25%
in
12 days
(closed on 01/10/09)
<> 
Start earning real money with zero risk while improving your trading skills and strategies at the UpDown Virtual Investing website -- just click on the image above or any of the text links to the site in this article to sign up today. My stats and profile are featured in the accompanying table and on my blog site below the last posted entry. I started trading at the UpDown on 11/23/08 with a gain of about 29% through today -- my profile name on the site is 'ETFinnovators' with a portfolio of long...
|
A New Global Healthcare Composite Index
DNDN
|
|
|
+2.90%
in
35 days
(closed on 12/28/08)
<> 
The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th...
|
A New Index of Emerging Biotech & Pharma Companies
DNDN
|
|
|
+0.00%
in
19 hours
(closed on 11/23/08)
<> 
<>
The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating.
The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett< />< /><><>< />< /><>...
|
Like the Playoffs-now I need help from others
DNDN
|
|
|
+285.08%
in
506 days
DNDN...Dendreon. If you haven't heard or read something about this stock recently, yo are reading the wrong pages, I guess. This shotup to mid 20's from 5 or 6 dollars after it was approved by the FDA advisory panel somewhat unanimously. this was about a year ago and again it shows my lack of knowledge, or OK greed at the time, not to get out with a nice little profit. <> any other newbies, don't make this mistake. I read the story in the wee hours of the night like now and put in a market order (I know some of you are screaming already) as I left for a doctors appointm<><><><><><>...
|
80 % airbag?
DNDN
|
|
|
+183.65%
in
680 days
<> You know from our previous posting that we have sold our position in DENDREON (DNDN - USD 7.70). We nevertheless want to keep an exposure in the stock. Dendreon has become a relative stable stock these days. That was different in the first half of the year with some erratic price action. A chart can be seen here: http://stockcharts.com/charts/gallery.html?dndn <> . The reason for the relative stable behaviour is that there is nothing spectacular to be expected from the biotech company in the near future. Only by the summer of next year the FDA will come up with its r...
|
Bullish on DNDN ...
DNDN
|
|
|
+185.43%
in
736 days
highly speculative.. I believe that the company's prostate cancer drug that FDA is currently reviewing for more data will ultimately get approved. Ans the stock will be a huge winner. But do realize that the downside will be substantial if the drug fails to get approved. More like a lottery ticket but upside reward is substantial.
|
Stage set for approval next year
DNDN
|
|
|
+155.86%
in
770 days
Dendreon on Thursday said the U.S. Food and Drug Administration has informed it that positive interim or final survival data from an ongoing trial of its Provenge cancer vaccine would satisfy the agency's earlier request for additional information on effectiveness of the product.
"We anticipate completing enrollment in the ... study this year and anticipate interim survival results in 2008,"
http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:...
|
People Bullish on DNDN
People Bearish on DNDN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on DNDN |
|
|
|
|
tanumoy
(+36.81% risk: conservative)
|
|
|
More Resources
|
About Dendreon Corp
- Answers.com
